Original researchImplementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
Cited by (0)
AHR and HGR shared first authorship. GMM and KF shared last authorship.
Contributors: AHR, HGR, GAG, OCL, ALBD, GMM and KF constituted the MetAction study management. AHR, HGR, DH, SD, KB, KTH, ALBD, GMM and KF contributed to the concept and design of the study. AHR, DH, SD and KB were the study oncologists. JTØ and CJ were the study nurses. SN, LJ, CHR and EAR were the study radiologists. HGR, TS, MLI and KB were the study pathologists. IRB, VS, MS and GAG were the study laboratory engineers. EH, VN, EAR, SN and OCL were the study bioinformaticians. VN, LSP, OØ, VAF, ALBD and GMM were the study molecular biologists. AHR, EA, HL and SJS performed the cost modeling. AHR drafted the manuscript. All authors read and approved the final version.
Funding: This work was supported by the Research Council of Norway (Grant number 218325). The funding source had no role in the study design, collection, analysis and interpretation of data, or the decision to make a scientific report. All of the authors had full access to the data. AHR had the final responsibility to submit the manuscript for publication.
Competing interests: None declared.
Ethics approval: The study was approved by the Institutional Review Board at the two study centres, Oslo University Hospital-Norwegian Radium Hospital and Akershus University Hospital, the Regional Committee for Medical and Health Research Ethics of South-East Norway (reference number REK 2013/2099) and the Norwegian Medicines Agency.
Provenance and peer review: Not commissioned; internally peer reviewed.